65,437 trials
Sarcoma, Soft Tissue
Primary: Progression Free Survival at Week 12 — 0; 0; 0; 0 participants — p=0.653
Infections, Papillomavirus
Primary: Number of Subjects Seroconverted for Anti-hepatitis A (Anti-HAV) Antibodies — 240; 242 Participants
Fibromyalgia Syndrome
Primary: Change From Baseline in Average Daily Pain Score to the Last 2 Weeks of the 12-week Treatment Phase (Based on the Full Analysis Set) — -1.12; -1.27; -0.83 Score on a scale
Cerebral Infarction · Atherosclerosis
Primary: Number of Participants With Progression of Symptomatic Intracranial Stenosis — 20; 32 participants
Influenza
Primary: Summary of Influenza Seroprotection Post-vaccination With Fluzone® Vaccine. — 44; 34; 31; 74 Percentage of Participants
Opiate-related Disorders · Opiate Dependence · Drug Abuse
Primary: Subject's Self Assessment Using 10 cm Visual Analogue Scale (VAS) of Overall Preference for One of the Two Buprenorphine-based Maintenance Therapies (Suboxone® or…
Tumor Lysis Syndrome · Cancer · Hyperuricemia
Primary: Plasma Uric Acid Responder — 80; 72; 60; 12 Participants — p=0.0009
Type 2 Diabetes
Primary: Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24 — -1.34; -1.62; -0.28 Percentage of hemoglobin — p=<0.001
Influenza
Primary: Percentage of Seroprotected Participants Post-vaccination With Fluzone® — 59; 34; 95; 80 Percentage of Participants
Chronic Idiopathic Thrombocytopenic Purpura · Purpura, Thrombocytopenic, Idiopathic
Primary: Number of Responders at Week 6 — 9; 0; 6; 8 Participants
Meningitis · Meningococcemia · Pertussis
Primary: Percentage of Participants With at Least a 4-fold Rise in Meningococcal Antibody Titer From Baseline (Day 0) to Day 28 Post-vaccination With Menactra® Vaccine. — 92; 94…
Attention Deficit Hyperactivity Disorder
Primary: Correlation Between Change From Baseline and 24 Week Endpoint in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent:Investigator-Administered and Scored…
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 910.95; 921.68 ng/mL
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 1,052.65; 1,078.46 ng/mL
Rheumatoid Arthritis
Primary: Number of Participants With American College of Rheumatology (ACR)20 at Week 12 of the Double-Blind Period — 21; 69; 62 Participants — p=0.026